Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Receptor-selective mutants of tumour necrosis factor in the therapy of cancer: preclinical studies.

Circulatory shock - 1 Aug 1994

Brouckaert P, Ameloot P, Cauwels A, Everaerdt B, Libert C, Takahashi N, Van Molle W, Fiers W

Abstract excerpt

The use of TNF-mutants that are selective agonists of the TNF-R55 is one strategy that is being explored to broaden the therapeutic margin of TNF. Several problems still have to be overcome before they can be used in clinical trials. Regarding the sensitizing effect of some infections and some tu...

Topics

Animals
Antigens, CD
Drug Tolerance
Mutation
Neoplasms, Experimental
Receptors, Tumor Necrosis Factor
Receptors, Tumor Necrosis Factor, Type I
Tumor Necrosis Factor-alpha

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 7895324

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026. Prepared record publication-7895324-2026-08-30.1. Manifest publication-graph-cohort-2026-08-30.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Receptor-selective mutants of tumour necrosis factor in the therapy of cancer: preclinical studies.PMID 7895324Read ↗

Phenotypic analysis of TNFR1-deficient mice and characterization of TNFR1-deficient fibroblasts in vitro.Semantic proximity Read ↗

Biological activity of mutants of human tumour necrosis factor-alpha.Semantic proximity Read ↗

Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic source.Semantic proximity Read ↗

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease.Semantic proximity Read ↗

Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1Semantic proximity Read ↗

Production and characterization of receptor-specific TNF muteins.Semantic proximity Read ↗

Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants.Semantic proximity Read ↗

Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology.Semantic proximity Read ↗

A novel tumor necrosis factor-alpha mutant with significantly enhanced cytotoxicity and receptor binding affinity.Semantic proximity Read ↗

Tumor necrosis factor receptor 2 plays a minor role for mycobacterial immunity.Semantic proximity Read ↗

Analysis of human tumour necrosis factor receptor 1 dominant-negative mutants reveals a major region controlling cell surface expression.Semantic proximity Read ↗

Inhibition of tumor necrosis factor-induced phenotypes by short intracellular versions of latent membrane protein-1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.